Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Carcinogenesis

• Publication date

  1987-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/CARCIN/8.9.1343PMID 3621472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response of carcinogen-altered mouse epidermal cells to phorbol ester tumor promoters and calcium.

  1987cited by this paper
• Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways.

  1986cited by this paper
• Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

  1986cited by this paper
• Cloning and expression of multiple protein kinase C cDNAs.

  1986cited by this paper
• Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor.

  1985cited by this paper
• Heterogeneity of [3H]phorbol 12,13-dibutyrate binding in primary mouse keratinocytes at different stages of maturation.

  1985cited by this paper
• Two-stage tumor promotion in mouse skin: an alternative interpretation.

  1985cited by this paper
• Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters.

  1985cited by this paper
• Specific binding of [20-3H]12-deoxyphorbol 13-isobutyrate to phorbol ester receptor subclasses in mouse skin particulate preparations.

  1983cited by this paper
• Regulation of epidermal transglutaminase activity and terminal differentiation by retinoids and phorbol esters.

  1983cited by this paper
• Divergent responses in epidermal basal cells exposed to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate.

  1982cited by this paper
• Initiator and promoter induced specific changes in epidermal function and biological potential.

  1981cited by this paper

• Regulation of selective class switching provides long-term therapeutic benefits for hay fever

  2025cites this paper
• Validation of Machine Learning-assisted Screening of PKC Ligands: PKC Binding Affinity and Activation.

  2025cites this paper
• Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors

  2024cites this paper
• Tumor microenvironment signaling and therapeutics in cancer progression

  2023cites this paper
• ProxyBind: A compendium of binding sites for proximity-induced pharmacology

  2022cites this paper
• Structure-Based Survey of the Human Proteome for Opportunities in Proximity Pharmacology

  2022cites this paper
• Targeting PKC in microglia to promote remyelination and repair in the CNS.

  2021cites this paper
• Structural insights into C1-ligand interactions: Filling the gaps by in silico methods.

  2021cites this paper
• The enigmatic protein kinase C (cid:1) : complex roles in cell proliferation and survival

  2020cites this paper
• Equivocal, explicit and emergent actions of PKC isoforms in cancer

  2020cites this paper
• Bryostatin 1 Promotes Synaptogenesis and Reduces Dendritic Spine Density in Cortical Cultures through a PKC-Dependent Mechanism.

  2020cites this paper
• Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: A mini-review.

  2020cites this paper
• Predicting Blood–Brain Barrier Permeability of Marine-Derived Kinase Inhibitors Using Ensemble Classifiers Reveals Potential Hits for Neurodegenerative Disorders

  2019cites this paper
• Oscillatoxin I: A New Aplysiatoxin Derivative, from a Marine Cyanobacterium

  2019cites this paper
• Bryostatin 1 alleviates respiratory syncytial virus pneumonia in a mice model via down-regulation of inflammatory cytokines

  2019cites this paper
• Natural product-derived compounds in HIV suppression, remission, and eradication strategies.

  2018cites this paper
• Potentials of PKC in cancer progression and anticancer drug development.

  2018cites this paper
• Spatial Regulation of PKC by Pharmacological Approaches in Cancer: Are We There Yet?

  2018cites this paper
• Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues

  2018cites this paper
• Characterization of AJH-836, a diacylglycerol-lactone with selectivity for novel PKC isozymes

  2018cites this paper
• Deletion of the C26 Methyl Substituent from the Bryostatin Analogue Merle 23 Has Negligible Impact on Its Biological Profile and Potency

  2018cites this paper
• Cultivable bacteria from Pectinatella magnifica and the surrounding water in South Bohemia indicate potential new Gammaproteobacterial, Betaproteobacterial and Firmicutes taxa

  2018cites this paper
• Protein kinase C in cancer: The top five unanswered questions

  2017cites this paper
• Bryostatin 1 causes attenuation of TPA‑mediated tumor promotion in mouse skin.

  2017cites this paper
• Oceans: Abode of Nutraceuticals, Pharmaceuticals, and Biotoxins

  2017cites this paper
• Bryostatin 1 inhibits reduction in viability and induction of apoptosis by hydrogen peroxide in Saos-2 , osteosarcoma cells through mitochondrial pathway

  2016cites this paper
• Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

  2016cites this paper
• Effects of exercise and bryostatin-1 on serotonin dynamics after cerebral infarction

  2016cites this paper
• Synthesis and Biological Evaluation of Several Bryostatin Analogues Bearing a Diacylglycerol Lactone C-Ring.

  2016cites this paper
• Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin

  2016cites this paper
• Structural optimization of 10-methyl-aplog-1, a simplified analog of debromoaplysiatoxin, as an anticancer lead

  2016cites this paper
• The expression of SLAMF7 levels in malignant B cells: a novel therapeutic pathway for patients with CLL

  2015cites this paper
• Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer’s disease, Parkinson’s disease and ischemic brain stroke: their molecular targets and action mechanisms

  2015cites this paper
• Neristatin 1 Provides Critical Insight into Bryostatin 1 Structure–Function Relationships

  2015cites this paper
• Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer’s disease, Parkinson’s disease and ischemic brain stroke: their molecular targets and action mechanisms

  2014cites this paper
• Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.

  2014cites this paper
• C1 domains: structure and ligand-binding properties.

  2014cites this paper
• Molecular Systems Pharmacology: Isoelectric Focusing Signature of Protein Kinase Cδ Provides an Integrated Measure of Its Modulation in Response to Ligands

  2014cites this paper
• Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.

  2013cites this paper
• Structure-activity studies on the side chain of a simplified analog of aplysiatoxin (aplog-1) with anti-proliferative activity.

  2013cites this paper
• Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.

  2012cites this paper
• Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines.

  2012cites this paper
• Specifying protein kinase C functions in melanoma

  2012cites this paper
• The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

  2012cites this paper
• Challenges to the development of bryostatin‐type anticancer drugs based on the activation mechanism of protein kinase Cδ

  2012cites this paper
• The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line.

  2011cites this paper
• Marine Organisms and Their Prospective Use in Therapy of Human Diseases

  2011cites this paper
• Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.

  2011cites this paper
• Protein Kinase C: An Attractive Target for Cancer Therapy

  2011cites this paper
• PKC isozymes in the control of fate of prostate cancer cells

  2011cites this paper
• Prevention of carcinogenesis and inhibition of breast cancer tumor burden by dietary stearate.

  2011cites this paper
• Phorbol Esters and Diacylglycerol: The PKC Activators

  2010cites this paper
• Bryostatin 1 Inhibits Phorbol Ester-Induced Apoptosis in Prostate Cancer Cells by Differentially Modulating Protein Kinase C (PKC) δ Translocation and Preventing PKCδ-Mediated Release of Tumor Necrosis Factor-α

  2010cites this paper
• Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.

  2010cites this paper
• Differentiation Therapy of Cancer : Journey from the Laboratory into the Clinic

  2009cites this paper
• Mitochondrial kinases in cell signaling: Facts and perspectives.

  2009cites this paper
• Postischemic PKC activation rescues retrograde and anterograde long-term memory

  2009cites this paper
• Identification and characterisation of ribosomal biosynthesis pathways of two cyclic peptides from cyanobacteria

  2009cites this paper
• Protein Kinase C Activators as Synaptogenic and Memory Therapeutics

  2009cites this paper
• Natural products AKTing on signal transduction pathways-molecules and methods

  2009cites this paper
• Drug development from marine natural products

  2009cites this paper
• Association of Changes in Norepinephrine and Serotonin Transporter Expression with the Long-Term Behavioral Effects of Antidepressant Drugs

  2009cites this paper
• Searching for Disease Modifiers—PKC Activation and HDAC Inhibition—A Dual Drug Approach to Alzheimer's Disease that Decreases Aβ Production while Blocking Oxidative Stress

  2009cites this paper
• Targeting protein kinase C (PKC) in physiology and cancer of the gastric cell system.

  2008cites this paper
• Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

  2008cites this paper
• Targeting the protein kinase C family: are we there yet?

  2008cites this paper
• Pharmaceuticals: Natural Products and Natural Product Models

  2008cites this paper
• Synergistic effects of chronic bryostatin-1 and alpha-tocopherol on spatial learning and memory in rats.

  2008cites this paper
• Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains

  2008cites this paper
• Differentiation Therapy in AML

  2007cites this paper
• Phorbol Esters: Structure, Biological Activity, and Toxicity in Animals

  2007cites this paper
• The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

  2007cites this paper
• Protein kinase C and other diacylglycerol effectors in cancer

  2007cites this paper
• Targeting the protein kinase C family: are we there yet?

  2007cites this paper
• Bryostatin 1 in Primary Mouse Epidermal Cells by Phorbol 12 , 13-Dibutyrate Contrasting Duration of Inhibition of Cell-Cell Communication

  2006cites this paper
• Protein Kinase C as the Receptor for the Phorbol Ester Tumor Promoters: Sixth Rhoads Memorial Award Lecture1

  2006cites this paper
• Potentiation of the Activity of l-ß-o-Arabinofuranosylcytosine by the Protein Kinase C Activator Bryostatin 1 in HL-60 Cells: Association with Enhanced Fragmentation of Mature DNA1

  2006cites this paper
• Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy

  2006cites this paper
• IFN-γ and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways

  2006cites this paper
• A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma

  2006cites this paper
• Preclinical and clinical development of novel agents that target the protein kinase C family.

  2006cites this paper
• Protein Kinase C as the Receptor for the Phorbol Ester Tumor Promoters : Sixth Rhoads Memorial Award Lecture 1

  2006cites this paper
• Synthesis and Pharmacological Evaluation of 8‐ and 9‐Substituted Benzolactam‐V8 Derivatives as Potent Ligands for Protein Kinase C, a Therapeutic Target for Alzheimer's Disease

  2006cites this paper
• Cyclin-dependent kinases as targets for cancer therapy.

  2006cites this paper
• IL-12-Independent Pathways Mechanisms Involving ERK-1 / 2-Dependent Cancer Patients Is Controlled through Dendritic Cells from Normal Donors and and T-bet Expression in Human γ IFN -

  2006cites this paper
• Phase I Study of Bryostatin 1 and Gemcitabine

  2006cites this paper
• The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2.

  2006cites this paper
• Overexpression of PKCepsilon sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1.

  2006cites this paper
• Association with Enhanced Fragmentation of Mature DNA by the Protein Kinase C Activator Bryostatin 1 in HL-60 Cells :d-Arabinofuranosylcytosine β Potentiation of the Activity of 1-Updated

  2006cites this paper
• Bryostatin-1: pharmacology and therapeutic potential as a CNS drug.

  2006cites this paper
• Phase I Study of Bryostatin1and Gemcitabine

  2006cites this paper
• Overexpression of PKCε sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1

  2006cites this paper
• The Antineoplastic Agent Bryostatin-1 Differentially Regulates IFN-γ Receptor Subunits in Monocytic Cells: Transcriptional and Posttranscriptional Control of IFN-γR21

  2006cites this paper
• Differential effects of bryostatin 1 and 12-O-tetradecanoylphorbol-13-acetate on the regulation and activation of RasGRP1 in mouse epidermal keratinocytes

  2006cites this paper
• Epidermal Cells Effects of Phorbol Ester Tumor Promoters on Primary Mouse Partial Parallelism and Partial Blockade by Bryostatin 1 of Updated

  2006cites this paper
• Prostratili, a Nonpromoting Phorbol Ester, Inhibits Induction by Phorbol 12-Myristate 13-Acetate of Ornithine Decarboxylase, Edema, and Hyperplasia in CD-I Mouse Skin

  2006cites this paper
• Posttranscriptional Control of IFN-Subunits in Monocytic Cells : Transcriptional Receptor γ Differentially Regulates IFN-The Antineoplastic Agent Bryostatin-1

  2006cites this paper
• Suppression of cell migration by protein kinase Cδ

  2005cites this paper
• Targeting protein kinase C and "non-kinase" phorbol ester receptors: emerging concepts and therapeutic implications.

  2005cites this paper
• Enhanced Expression of CD20 in Human

  2005cites this paper